• New Merck COVID Efforts-2 Vaccines+Antiviral Drug EIDD-2801; Acquisition & Collaborations - (05/26/20)
   
  
• Long-acting drug acts like a short-term AIDS vaccine (Cabotegravir injectable long-acting HPTN-083 study) - (05/22/20)
   
  
• Cabotegravir Injectable Long Acting PrEP Study HPTN-083 Stopped Due To Higher Efficacy - (05/22/20)
   
  
• Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial - (05/21/20)
   
  
• CROI: Creation of Long - Acting Nanoformulated Tenofovir Prodrugs - (05/21/20)
   
  
• Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection FLAIR - (05/21/20)
   
  
• Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression ATLAS - (05/21/20)
   
  
More HIV Articles...
 

• Coronavirus puts drug repurposing on the fast track - (03/02/20)
   
  
• FDA Expands Coronavirus Testing in the United States - (03/02/20)
   
  
• Vice President Pence Announces Ambassador Debbie Birx to Serve as the White House Coronavirus Response Coordinator - (02/27/20)
   
  
More News Updates Articles...
 

• HCV & HCV/HIV Coinfection Micro-Elimination Grants: funding for 30+ projects - -
   
  
• EASL: Summary from EASL 2018 for Hepatitis C (HCV) HCV in 2018: Success stories and remaining challenges? - Prof. Dr. J.K. Rockstroh Department of Medicine I University of Bonn Sigmund-Freud-Str. 25 53105 Bonn Germany-
   
  
• EASL: HCV Micro-Elimination Funding Grants Available
   
  
• HCV Elimination in Australia vs USA - (05/21/20)
   
  
• VAT & Fatty Liver/Fibrosis - "Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD" - (05/15/20)
   
  
• New HCV Infections Tripled: 4 times Higher than in 2009 - (05/14/20)
   
  
• Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection - (05/14/20)
   
  
More Hep C Articles...
 

• Study Finds Highly Elevated Levels of Fatty Liver Disease for 9/11 First Responders - (05/11/20)
   
  
• VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial - press release - (04/20/20)
   
  
• Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection - (04/20/20)
   
  
More Hep B Articles...
 

List not necessarily listed here in order of date being held.